The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective cytotoxic activity in neuroblastoma
Our recent study revealed that the chemotherapeutic CX-5461 primarily binds and inhibits TOP2B, exhibiting selective cytotoxicity in neuroblastoma cells, which overexpress TOP2B. As such, pharmacological targeting of TOP2B raises safety concerns due to off-target drug interactions with this gene.
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150
Proton pump inhibitors (PPIs) are commonly used concomitant to cancer treatment and they induce gut microbiota changes. It’s increasingly apparent that gut dysbiosis can reduce the effectiveness of immune checkpoint inhibitors (ICI). However, little is known on PPI effects on outcomes with ICIs.
EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers
Sorting Nexin 3 (SNX3), a member of the recycling retromer complex, is a critical player in the epidermal growth factor (EGF) stimulated EGFR network in triple-negative breast cancers.
A negative NKX2-1/DUSP6/ERK signal inhibits lung cancer
Lung cancer is the #1 cancer killer in the U.S. Lung cancer’s heterogenous pathology and complicated oncogenic signaling networks have impeded care.
Higher Bleeding Rates Found with Direct Oral Anticoagulants in Myeloproliferative Neoplasm Patients
In this study we evaluated thrombosis and bleeding outcomes in myeloproliferative neoplasm (MPN) patients treated with direct oral anticoagulants (DOACs). We found an unexpected high cumulative incidence of bleeding, emphasizing the need for continued rigorous evaluation of DOACs in MPNs.
The role of the stroma, encompassing pancreatic stellate cells and extracellular matrix, in the biology and chemoresistance of pancreatic cancer
Our report entitled “3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing” (PMID: 23446043) has its ten years anniversary. Herein we present the story "After the Paper" on the background of two recent publication from our group.
